• Dominguez MC, Lorenzo N, Barbera A, Darrasse-Jeze G, Hernández MV, Torres A, et al. An altered peptide ligand corresponding to a novel epitope from heat-shock protein 60 induces regulatory T cells and suppresses pathogenic response in an animal model of adjuvant-induced arthritis. Autoimmunity. 2011;44(6):471-82. doi: 10.3109/08916934.2010.550590 or https://pubmed.ncbi.nlm.nih.gov/21370936/.

• Lorenzo N, Barberá A, Domínguez MC, Torres AM, Hernandez MV, Hernandez I, et al. Therapeutic effect of an altered peptide ligand derived from heat-shock protein 60 by suppressing of inflammatory cytokines secretion in two animal models of rheumatoid arthritis. Autoimmunity. 2012;45(6):449-59. doi: 10.3109/08916934.2012.697592 or https://pubmed.ncbi.nlm.nih.gov/22686732/.

• Domínguez MC, Lorenzo N, Barberá A, Padrón G, Torres AM, Hernández MV, et al. Therapeutic effect of two altered peptide ligands derived from the human heat shock protein 60 in experimental models of rheumatoid arthritis. Biotecnología Aplicada. 2013;30:153-6. Available in: https://elfosscientiae.cigb.edu.cu/PDFs/Biotecnol%20Apl/2013/30/2/BA003002RP153-156.pdf or http://scielo.sld.cu/scielo.php?pid=S1027-28522013000200011&script=sci_abstract&tlng=pt.

• Domínguez M, Lorenzo N, Cantera D. A Peptide as Immunomodulator for the Treatment of Juvenile Idiopathic Arthritis. Annals of the Rheumatic Diseases. 2014;73:130. DOI: 10.1136/annrheumdis-2014-eular.1908 or https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4908004/.

• Barberá A, Lorenzo N, Van Kooten P, Van Roon J, De Jager W, Prada D, Gómez J, Padrón G, Van Eden W, Broere F, Domínguez MC. APL1, an altered peptide ligand derived from human heat-shock protein 60, increases the frequency of Tregs and its suppressive capacity against antigen responding effector CD4 + T cells from rheumatoid arthritis patients. Cell Stress Chaperones. 2016;21(4):735-44. DOI: 10.1007/s12192-016-0698-0 or https://pubmed.ncbi.nlm.nih.gov/27241313/.

• Lorenzo N, Altruda F, Silengo L, Del Carmen Dominguez M. APL-1, an altered peptide ligand derived from heat-shock protein, alone or combined with methotrexate attenuates murine collagen-induced arthritis. Clin Exp Med. 2017;17(2):209-216. doi: 10.1007/s10238-016-0412-7 or https://pubmed.ncbi.nlm.nih.gov/27160252/.

• Cabrales-Rico A, Ramos Y, Besada V, Domínguez M, Lorenzo N, García O, et al. Development and validation of a bioanalytical method based on LC-MS/MS analysis for the quantitation of CIGB-814 peptide in plasma from Rheumatoid Arthritis patients. J Pharm Biomed Anal. 2017;143:130-140. doi: 10.1016/j.jpba.2017.05.030 or https://pubmed.ncbi.nlm.nih.gov/28595106/.

• Prada D, Gómez J, Lorenzo N, Corrales O, López A, et al. Phase I Clinical Trial with a Novel Altered Peptide Ligand Derived from Human Heat-Shock Protein 60 for Treatment of Rheumatoid Arthritis: Safety, Pharmacokinetics and Preliminary Therapeutic Effects. J Clin Trials. 2018;8:339. doi:10.4172/2167-0870.1000339 or https://www.readcube.com/articles/10.4172/2167-0870.1000339.

• Corrales O, Hernández L, Prada D, Gómez J, Reyes Y, López AM, González LJ, Domínguez M. CIGB-814, an altered peptide ligand derived from human heat-shock protein 60, decreases anti-cyclic citrullinated peptides antibodies in patients with rheumatoid arthritis. Clin Rheumatol. 2019 Mar;38(3):955-960. doi: 10.1007/s10067-018-4360-3 or https://pubmed.ncbi.nlm.nih.gov/30415439/.

• Domínguez MC, Cabrales A, Lorenzo N, Padrón G, Gonzalez LJ. Biodistribution and pharmacokinetic profiles of an altered peptide ligand derived from heat-shock proteins 60 in Lewis rats. Cell Stress Chaperones. 2020;25(1):133-140. doi: 10.1007/s12192-019-01054-3 or https://pubmed.ncbi.nlm.nih.gov/31802366/.

• Cimino R, Savioli M, Carrante NF, Placidi E, Garay-Perez H, López-Abad M, Lasa AM, Domínguez-Horta MC, et al. Aggregation properties of a therapeutic peptide for rheumatoid arthritis: A spectroscopic and molecular dynamics study. Chem Phys Mater. 2022;1(1):62-70. DOI: https://doi.org/10.1016/j.chphma.2021.09.007 or https://www.sciencedirect.com/science/article/pii/S2772571521000073.

• Venegas-Rodriguez R, Santana-Sanchez R, Peña-Ruiz R, Bequet-Romero M, Hernandez-Cedeño M, Santiesteban-Licea B, et al. CIGB-258 Immunomodulatory Peptide: Compassionate Use for Critical and Severe COVID-19 Patients. Austin J Pharmacol Ther. 2020; 8(1).1119. Available in: https://austinpublishinggroup.com/pharmacology-therapeutics/fulltext/ajpt-v8-id1119.pdf.

• Venegas-Rodríguez R, Peña-Ruiz R, Santana-Sánchez R, Bequet-Romero M, Hernández-Cedeño M, Santiesteban-Licea B, García A, Aroche-de-Dios P, Oliva-Pérez D, Rosario-Cruz L, Esquivel-Moynelo I, García-Sánchez M, Martínez-Donato G, Guillén-Nieto G, Domínguez-Horta M. Péptido inmunomodulador CIGB-258 para el tratamiento de pacientes graves y críticos con la COVID-19. Revista Cubana de Medicina Militar. 2020;49(4). Available in: https://revmedmilitar.sld.cu/index.php/mil/article/view/926.

• González-Zorrilla M, González-Mesana R, Hernández-Cedeño M, Bequet-Romero M, Rosario-Cruz L, Grecesqui-Cruz I, Guzmán-Noa N, Pérez-Aguilera L, Chacón -Montano D, Penton-Arias E, Guillen-Nieto G, Venegas-Rodriguez R, Dominguez-Horta MC. CIGB-258, An Immunomodulatory Peptide for the Treatment of a COVID-19-associated Hepatic Encephalopathy: A Case Report. Preprints 2020 (www.preprints.org) | NOT PEER-REVIEWED | Posted: 11 September 2020. En revisión en Journal NeuroVirology, 2020090240. DOI: 10.13140/RG.2.2.32928.81922 or https://www.researchgate.net/publication/345180506_CIGB-258_An_Immunomodulatory_Peptide_for_the_Treatment_of_a_COVID-19-associated_Hepatic_Encephalopathy_A_Case_Report.

• Hernandez-Cedeño M, Venegas-Rodriguez R, Peña-Ruiz R, Bequet-Romero M, Santana-Sanchez R, Penton-Arias E, Martinez-Donato G, Guillén-Nieto G, Dominguez-Horta MDC. CIGB-258, a peptide derived from human heat-shock protein 60, decreases hyperinflammation in COVID-19 patients. Cell Stress Chaperones. 2021;26(3):515-525. doi: 10.1007/s12192-021-01197-2 or https://pubmed.ncbi.nlm.nih.gov/33629254/.

• Rubio Ortega Rafael, Rodríguez Moya Valentín Santiago, Leiva Machado Mariani, Domínguez Dorta María del Carmen. Uso del péptido CIGB-258 en un paciente pediátrico con neumonía grave por SARS-CoV-2. Rev Cubana Pediatr. 2021;93(3):e1572. Available in: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S0034-75312021000300017&lng=pt.

• Venegas-Rodríguez R, Serrano-Díaz A, Peña-Ruiz R, Santana-Sánchez R, Rittoles-Navarro A, Grecesqui-Cruz I, Pérez-Aguilera L, Segura-Fernández A, Hernández-Cedeño M, Rosario-Cruz L, Chacón-Montano D, Martínez-Donato G, Guillén-Nieto G, Domínguez-Horta M. El tratamiento con Jusvinza disminuye la hiperinflamación y la hipercoagulación en pacientes críticos con la COVID-19. Revista Cubana de Medicina Militar. 2021;50(4). Available in: https://revmedmilitar.sld.cu/index.php/mil/article/view/1675.



Jusvinza

PUBLICATIONS

• Baldomero J, Del Río A, Cruz LR, Venegas R, Hernández M, Serrano A, Peña R, Esquivel I, Fernández T, Martínez A, Graña J, Suñol D, Sánchez F, Domínguez R, Roca Z, Salina-Caballero Y, Viera A, Marrero O, Martínez G, Muzio VL, Guillén G, Domínguez MC. Early Treatment with a Peptide Derived from the Human Heat-Shock 60 Protein Avoids Progression to Severe Stages of COVID-19. Journal of Biotechnology and Biomedicine. 2021;4:196-210. Available in: https://www.fortunejournals.com/articles/early-treatment-with-a-peptide-derived-from-the-human-heatshock-60-protein-avoids-progression-to-severe-stages-of-covid19.html or DOI:10.26502/jbb.2642-91280045.

• Dominguez-Horta M, Venegas-Rodríguez R, Guillén-Nieto G, Martínez-Donato G, Hernández-Cedeño M, Bequet-Romero M, Peña-Ruiz R, Santana-Sánchez R, González L, Cabrales A, Padrón G, Cruz L, Esquivel-Moynelo I. CIGB-258, péptido inhibidor de la hiperinflamación en pacientes con COVID-19. Anales de la Academia de Ciencias de Cuba. 2022;12(1). Available in: http://www.revistaccuba.cu/index.php/revacc/article/view/1072.